Introduction {#S0001}
============

Data from GLOBOCAN 2012, produced by the International Agency for Research on Cancer, indicated that an estimated 14.1 million new cancer cases and 8.2 million cancer deaths occurred in 2012 worldwide.[@CIT0001] This trend has not been curbed by the progress of medical research.

Because low health-related quality of life (HRQOL), especially resulting from inadequate treatment (eg, chemotherapy), may deteriorate cancer patients' condition and even increase mortality,[@CIT0002] the HRQOL is a central consideration for many physicians in their decision-making process in catering to different treatment options.[@CIT0003],[@CIT0004] Identifying the efficacy of long-term treatment strategies in improving low HRQOL in patients with cancer is of paramount importance.

Complementary and integrative medicine (CIM), according to the National Center for Complementary and Integrative Health, refers to the non-mainstream therapies which can be used along with conventional treatment. In general, it encompasses many diverse therapies including natural products (such as herbs and botanicals), mind and body practices (such as acupuncture, massage and mediation), and other complementary health approaches.[@CIT0005] With more interest in CIM and a growing body of evidence supporting the use of CIM among patients with cancer, more medical clinics and cancer centers are trying to address public interest and demand by providing CIM services.[@CIT0006]--[@CIT0008] Unfortunately, many integrative practices remain under study, with insufficient evidence to be definitively recommended. The best CIM method for cancer patients has not yet been established. Therefore, in the present systematic review, we examined the randomized clinical trial (RCT) evidence to compare the relative efficacy of different CIM interventions, hoping to provide significant information for patients, health-care practitioners, and policy makers on the course of tumor treatment prescription to treat low HRQOL in patients with cancer.

Materials and methods {#S0002}
=====================

We followed the PRISMA guidelines for this systematic review and meta-analysis.[@CIT0009] A previously established protocol registered with PROSPERO (CRD42018091609) was conducted and associations of each CIM with HRQOL were compared using a direct meta-analysis and Bayesian network meta-analysis. Good research practices on indirect treatment comparisons, as emphasized in the International Society for Pharmacoeconomics and Outcomes Research Task Force, were rigorously followed[@CIT0010],[@CIT0011] and quality of evidence was appraised by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria.[@CIT0012]

Search strategy and selection criteria {#S0002-S2001}
--------------------------------------

We searched PubMed, MEDLINE, Embase, Web of Science, Cochrane Central, and Clinical Trial registries (<http://www.clinicaltrials.gov> and <http://www.clinicaltrialsregister.eu>) from inception to February 14, 2018. We also manually screened published systematic reviews and presentations from major conference proceedings such as the American Society of Clinical Oncology for additional studies. The references of the final included articles were also reviewed. The search was conducted by two investigators (MFZ and WFL) independently.

The search terms were "CIM", "complementary and integrative medicine", "complementary and alternative therapies", "complementary medicine", "alternative medicine", "integrative medicine", "HRQOL", "quality of life", "health related quality of life", "life quality", "neoplasia", "tumor", "cancer", "malignant neoplasm", "oncology", "onco\*", and "integrative oncology".

To be eligible, RCTs comparing CIM-based intervention with a control group receiving no intervention for psychological functioning and HRQOL in patients with cancer were included. In addition, selected evaluation tools for overall HRQOL were those HRQOL questionnaires which were most widely used in clinical research, including the Functional Assessment of Cancer Therapy (FACT),[@CIT0013] Functional Assessment of Chronic Illness Therapy (FACIT),[@CIT0014] MD Anderson Symptom Inventory (MDASI),[@CIT0015] 36-item Short Form Health Survey 36 (SF-36),[@CIT0016] and European Organisation for Research and Treatment of Cancer (EORTC).[@CIT0017]

We excluded observational studies, trials with unclear effective CIM treatments (eg, music therapy and aromatherapy), and studies conducted in special populations (eg, patients with mental illness or care), to avoid excessive heterogeneity.

Data abstraction and quality assessment {#S0002-S2002}
---------------------------------------

Data from the included studies were extracted by two authors (YRZ and HW) independently on to a standardized form including the name of study, first author, study design, and blinding; patient characteristics; and the frequency, duration, and schedule of the primary intervention. The primary outcome was the HRQOL score changes between baseline and after treatment, which were measured in terms of several multidimensional generic questionnaires consisting of multiple domains such as physical well-being, social well-being, emotional well-being, sleep quality, and fatigue. All data were abstracted using study-reported modified intention-to-treat analysis. Data abstraction discrepancies were resolved by consensus in consultation with a third reviewer (ZHZ). The risk of bias of an individual study was assessed in the context of the primary outcome using the Cochrane Risk of Bias assessment tool.[@CIT0018]

Quality of evidence {#S0002-S2003}
-------------------

We assessed the quality of evidence of estimates derived from network meta-analysis using the GRADE methodology.[@CIT0012],[@CIT0019] For direct comparisons in this system, RCTs start at high quality and may be downgraded to levels of moderate, low, and very low quality owing to heterogeneity, risk of bias, indirectness, imprecision, and/or publication bias. For the indirect estimates, it starts at the lowest rating of the two pairwise estimates that contribute as first-order loops, but may be further downgraded in consideration of imprecision or intransitivity (heterogeneity such as different clinical or methodological characteristics). The higher rating of the direct or indirect estimates would be applied to the network meta-analysis if their ratings were similar.

Statistical analysis {#S0002-S2004}
--------------------

The DerSimonian and Laird random-effects model was used for direct meta-analysis to estimate pooled standardized mean differences (SMDs) and 95% CI incorporating within- and between-study heterogeneity.[@CIT0020] The *I*^2^ statistic was calculated to assess study heterogeneity.[@CIT0021] The Hartung--Knapp method was used to address possible type I errors in post-hoc sensitivity analyses.[@CIT0022] Funnel-plot symmetry and Egger\'s regression test were used to assess the publication bias, with the test value *P*\<0.05 indicating publication bias.[@CIT0023]

For the indirect meta-analysis, we performed a random-effects network meta-analysis in ADDIS version 1.14.1. Network meta-analysis models in ADDIS are implemented in the Bayesian framework and estimated using Markov chain Monte Carlo (MCMC) methods.[@CIT0024] This approach is recommended by the National Institute for Health and Care Excellence (NICE) Decision Support Unit technical support documents on evidence synthesis.[@CIT0025] Since this network meta-analysis is an indirect comparison based on the comparison of placebo/conventional care without CIM and multiple CIMs, statistical analysis is performed directly under the consistency model without the need to carry out consistent tests. Statistical significance was assessed using 95% CI, with CI spanning 1 indicating *P*\>0.05, suggesting no statistical significance. Then, a network diagram was drawn and finally a rank-order graph of each CIM was constructed.

Results {#S0003}
=======

Characteristics of the included studies {#S0003-S2001}
---------------------------------------

In total, 574 unique studies were found using the search strategy, most of which were duplicate records or not reporting RCTs. Thus, 149 full-text articles were fully reviewed according to the inclusion and exclusion criteria, resulting in a final sample of 34 studies ([Figure 1](#F0001){ref-type="fig"}). All studies are two-arm trials, in which one arm is a CIM intervention, including yoga (eight trials), nutritional supplement (NS) (six trials), Chinese herbal medicine (CH) (four trials), acupuncture (four trials), multimodal complementary medicine (MCM) (three trials), qigong (three trials), mindfulness (MM) (three trials), massage (two trials), or qigong plus MM (one trial), while the other arm is placebo or usual care without CIM treatment.Figure 1Flowchart of the study identification and selection process.**Abbreviations:** CIM, complementary and integrative medicine; HRQOL, health-related quality of life; RCT, randomized clinical trial.

The characteristics of patients included in the RCTs enrolled in this review are summarized in [Table 1](#T0001){ref-type="table"}. Overall, these 34 trials were reported between 2006 and 2017 and included 3,010 participants (the range of size of trials was 13 to 275 participants). The primary outcome (HRQOL score changes) was reported in all studies. Among the trials, 16 trials were from the USA, five trials from Germany, four trials from China, four trials from Australia, two trials from Japan, and two trials from the UK; and South Korea, Malaysia, Turkey, and Italy each had one trial. The age of patients ranged from 44.7 to 70.3 years (median 56 years) across all studies, and 92% were female. Breast cancer (20 studies) was the most studied cancer among the enrolled studies, followed by various cancers (seven studies), colorectal cancer (three studies), prostate cancer (one study), lung cancer (one study), hepatic carcinoma (one study), and ovarian cancer (one study). The mean HRQOL score of patients at the baseline of CIM treatment was 82.5 (range 20.7--152.1), while it was 80.4 (range 16.6--143.2) in the control group. However, after treatment, the mean HRQOL score of patients in the CIM group was 87 (range 24.4--145.2), while it was 81.8 (range 20--131.4) in the control group.Table 1Characteristics of the included randomized clinical trials comparing CIM interventions vs controlCIM typeStudyYearCountryPeriodAge (years): mean (SD)Female: n (%)mITT/completersSpecific method^a^CancerOutcomes of interest reportedInterventionControlHRQOLFatigueEmotionalPhysicalSocialSleepYogaCramer et al[@CIT0026]2014GermanySept 2012--Dec 2013I: 68.70 (9.13); C: 67.81 (10.37)21 (38.9)2727272790 min/t, 1 weeklyColorectal√√√√√√Harder et al[@CIT0027]2015UKApr 2011--May 2013I: 54.6 (10.9); C: 55.8 (11.6)92 (100)46314633N/A, ≥1 weeklyBreast√√√√Siedentopf et al[@CIT0028]2013GermanyJun 2008--Nov 2009I: 55.82 (10.72); C: 58.41 (9.91)93 (100)49304423N/A, 2 weeklyBreast√Littman et al[@CIT0029]2012USAMay 2007--Apr 2008I: 60.6 (7.1); C: 58.2 (8.8)63 (100)32273127N/A, 5 weeklyBreast√√√√√Chandwani et al[@CIT0030]2010USAN/AI: 51.39 (7.97); C: 54.02 (9.96)61 (100)30273129120 min/t, 1 weeklyBreast√√√√Moadel et al[@CIT0031]2007USA2001--2005I: 55.11 (10.07); C: 54.23 (9.81)128 (100)1088456441.5 h/t, 1 weeklyBreast√√√√√Pruthi et al[@CIT0032]2012USANov 2010--Aug 2011I: 58 (6.8); C: 55 (8.3)30 (100%1511151060 min/t, 8 weeklyBreast√Ben-Josef et al[@CIT0033]2017USAOct 2014--Jan 2016I: 66.2 (5.3); C: 68.2 (7.3)68 (100)3522332875 min/t, 2 weeklyProstate√Nutritional supplementLesser et al[@CIT0034]2013USASept 2004--Mar 2009I: 52 (13.5); C: 50 (11)236 (100)1227811461CoQ10+ vitamin E: 300 mg/300 IU, 3/d, poBreast√√√Lustberg et al[@CIT0035]2017USANov 2011--Oct 2013I: 61.2 (6.6); C: 57.8 (9.1)44 (100)22172215EPA + DHA; 4.3 g/day, poBreast√√√√Noguchi et al[@CIT0036]2014JapanFeb 2012--May 2012I: 50.5 (14.0); C: 51.2 (10.9)45 (100)15111513Biorinck granule (Chlorella granules); 4 sticks/d, poBreast√√√Norman et al[@CIT0037]2006GermanyNov 2008--Nov 2009I: 65.10 (12.55); C: 61.6 (13.82)11 (35.5)16161515Creatine monohydrate: 20 g/d (first week); 5 g/d (maintainence phase), poColorectal√√√√√Can et al[@CIT0038]2009TurkeyOct 2005--Dec 200654.32 (12.77)^e^13 (35)20172020Kefir: 250 mL ×2/d, poColorectal√√√√Cruciani et al[@CIT0039]2009USAN/AI: 66.5 (12.8); C: 70.3 (12.9)16 (55)1710127L-carnitine: 0.5 g/d (initial 2 days), 1 g/d (second 2 days), 2 g/d (maintainence phase), poVarious√√√√√Chinese herbal medicineHan et al[@CIT0040]2016ChinaSep 2011--Mar 2014I: 59.19 (9.44); C: 59.63 (10.06)42 (40.6)53525347Herb compound decoction: 200 mL ×2/day, poLung√Marx et al[@CIT0041]2017AustraliaMar 2014--Feb 2015I: 57 (14); C: 59 (11)32 (63)24152719Ginger capsule: 300 mg ×4/d, poVarious√Tian et al[@CIT0042]2010ChinaSep 2005--May 2008I: 51.44 (10.5); C: 52.37 (10.81)16 (16.5)49494848Ganji decoction: 1 dose/d, po + ailitong (a Chinese medical pad-shaped plaster preparation): 2/d for 10 days, externally appliedHepatic√√Jeong et al[@CIT0043]2010KoreaMay 2009--Oct 2009I: 49.4 (10.8); C: 53.4 (8.0)25 (62.5)20182018Bojungikki-tang: 2.5 g ×3/d, poVarious√√AcupunctureJohnston et al[@CIT0044]2011USAN/AI: 55 (6.4); C: 53 (7.2)NS667650 min, 8 weeklyBreast√√Smith et al[@CIT0045]2013AustraliaApr 2010--Feb 2011I: 55 (8.8); C: 58 (7.5)30 (100)1091010A total of 5 needles, stimulated manually and retained for 20 min, 2 weekly (initial), 1 weekly (final 3 weeks)Breast√√Zick et al[@CIT0046]2016USAMar 2011--Oct 2014I: 59.7 (9.4); C: 61.0 (10.0)288 (100)98719683A total of 5 needles, stimulated manually and retained for 30 min, dailyBreast√√√√√Deng et al[@CIT0047]2013USAAug 2004--Apr 2009I: 54 (8.9); C: 53 (10.4)80 (82)49345240A total of 14 needles, stimulated manually and retained for 20 min, 1 weeklyVarious√Multimodal complementary medicineSpahn et al[@CIT0048]2013GermanyN/AI: 58.1 (8.5); C: 55.3 (11.4)64 (100)323032256 h/t, daily ^b^Breast√√√√√Domnick et al[@CIT0049]2017Germany2009--2010I: 60 (10); C: 60.8 (10)67 (67)5050505035--40 min/t, 1--4 weekly ^c^Various√√Witt et al[@CIT0050]2015ItalyApr 2011--Mar 2012I: 56.3 (10.9); C: 56 (11)275 (100)136114139113N/A^d^Breast√√√√√√QigongChen et al[@CIT0051]2013China2005--2007I: 45.3 (6.3); C: 44.7 (9.7)96 (100)4949474640 min/t, 5 weeklyBreast√√√Liu et al[@CIT0052]2017Hong Kong2012--2013I: 50.9 (7.0); C: 51.3 (7.3)158 (100)79457960\>40 min/t, dailyBreast√Loh et al[@CIT0053]2014Malaysia2010--2011N/A132 (100)6632663230 min/t, 2 weeklyBreast√√√√MindfulnessBlaes et al[@CIT0054]2016USA2012--2013I: 55 (10); C: 57 (10)38 (90.5)282414112.5 h/t, 8 weeklyVarious√√√Milbury et al[@CIT0055]2013USAOct 2007--2012I: 53.0 (6.6); C: 54.1 (8.6)42 (100)1818242360 min/t, 2 weeklyBreast√√√√√Reich et al[@CIT0056]2017USAFeb 2009--Sept 201356.6 ^f^51 (100)2415271915--45 min/t, dailyBreast√√√√MassageSharp et al[@CIT0057]2010UKJun 2002--Feb 2005I: 57.7 (10.12); C: 59.36 (10.23)123 (100)616162621 h/t, 1 weeklyBreast√√√√Judson et al[@CIT0058]2011USA2006--2009I: 58.8 (13); C: 63 (9)45 (100)2222232330 min/t, 1 weeklyOvarian√Qigong + mindfulnessOh et al[@CIT0059]2012AustraliaOct 2007--May 2008I: 64.6 (12.3); C: 61.1 (11.0)38 (47)3723443190 min, 2 weekly ^e^Various√[^2]

Quality assessment and risk of bias of the included trials {#S0003-S2002}
----------------------------------------------------------

Using Cochrane's Risk of Bias assessment tool, the result indicated that 11 studies were scored as high quality. Most studies scored high risk are ascribed to the bias on blinding of personnel, since blinding of personnel was not applicable during the exercise interventions. Furthermore, several studies were judged as unclear risk of bias in random sequence generation, allocation concealment, blinding of participants and personnel, and blinding of outcome assessment. The results are shown in [Figure 2](#F0002){ref-type="fig"}.Figure 2Quality assessment of the trials included in the analysis: review authors' judgments about each risk of bias item for all included studies (**A**), and for each included study (**B**).

Direct meta-analysis of the included studies {#S0003-S2003}
--------------------------------------------

After extracting the data of the included studies, available direct comparisons and network of trials were compiled and are shown in [Figure 3](#F0003){ref-type="fig"}. All agents were associated with HRQOL and CIMs compared with placebo/usual care without CIMs. In post-hoc sensitivity analysis using the Hartung--Knapp method, all results were consistent. The results indicated that, taking usual care without CIM treatment as a comparator, all the CIM treatments reported the effects on HRQOL and emotional well-being. Most enrolled studies compared yoga and NS with control on all the treatment efficacy evaluation dimensions, such as HRQOL and emotional well-being. Furthermore, for the change in HRQOL from endpoint to baseline, we used direct meta-analysis and the results showed that all the subgroups of different CIM treatments did not show obvious heterogeneity. Therefore, a fixed-effect model was employed to test the effects. The test for total effect showed clearly superior efficacy of CIM treatments in improving HRQOL (mean difference 3.99 \[2.32, 5.67\]), although subgroup analysis demonstrated that only CH (mean difference 6.03 \[0.15, 11.92\]) and qigong + MM (mean difference 12.66 \[8.75, 16.57\]) was significantly favored over usual care ([Figure 4](#F0004){ref-type="fig"}). On the other hand, for the multiple domains related to HRQOL, the overall effect for total CIM treatments may improve emotional (SMD 0.18 \[0.05, 0.31\]) and physical well-being (SMD 0.22 \[0.06, 0.37\]), with moderate heterogeneity ([Table 2](#T0002){ref-type="table"}). Yoga seems to aggravate sleep quality (SMD −0.81 \[−1.18, −0.08\]), which is contrary to the traditional conception that yoga may reduce sleep problems.[@CIT0060]Table 2Summary of direct meta-analysis for different domains of quality of lifeCIM treatmentsFatigue scoresEmotional scoresPhysical scoresSocial scoresSleep scoresNo. of studiesSMD (95% CI)*I*^2^No. of studiesSMD (95% CI)*I*^2^No. of studiesSMD (95% CI)*I*^2^No. of studiesSMD (95% CI)*I*^2^No. of studiesSMD (95% CI)*I*^2^Yoga3[@CIT0026],[@CIT0028]--[@CIT0031]0.17 (−0.09, 0.43)0%5[@CIT0026],[@CIT0030]--[@CIT0033]0.24 (−0.06, 0.54)53%5[@CIT0026],[@CIT0027]--[@CIT0029],[@CIT0033]0.4 (0.02, 0.78)70.4%\*5[@CIT0026],[@CIT0030]--[@CIT0033]0.14 (−0.08, 0.34)0%1[@CIT0026]−0.81 (−1.18, −0.08)0%\*Mindfulness3[@CIT0054]--[@CIT0056]0.13 (−0.44, 0.70)75%2[@CIT0055],[@CIT0056]0.09 (−0.36, 0.54)54%1[@CIT0056]−0.11 (−0.72, 0.50)0%---------3[@CIT0054]--[@CIT0056]−0.38 (−1.24, 0.53)89%Chinese herbal medicine1[@CIT0043]0.43 (−0.20, 1.05)0%1[@CIT0040]0.27 (−0.13, 0.67)0%---------------------------Nutritional supplement3[@CIT0034],[@CIT0036],[@CIT0039]0.09 (−0.61, 0.79)77%5[@CIT0035]--[@CIT0039]0.21 (−0.29, 0.71)62%4[@CIT0035]--[@CIT0038]0.07 (−0.33, 0.47)31%5[@CIT0035]--[@CIT0039]0.11 (−0.19, 0.41)0%---------Qigong1[@CIT0053]0.17 (−0.23, 0.57)0%1[@CIT0053]0.13 (−0.36, 0.62)0%---------1[@CIT0052]−0.47 (−0.97, 0.02)0%1[@CIT0051]0.17 (−0.23, 0.57)0%Qigong + mindfulness---------------------------------------------Acupuncture1[@CIT0044]−0.07 (−0.94, 0.81)0%1[@CIT0044]0.3 (0.02, 0.59)0%\*1[@CIT0047]0.17 (−0.12, 0.45)0%1[@CIT0047]0.08 (−0.22, 0.34)0%1[@CIT0045]−0.23 (−0.52, 0.05)0%Massage---------1[@CIT0057]0.18 (−0.18, 0.53)0%---------1[@CIT0057]0.03 (−0.32, 0.38)0%---------Multimodal complementary medicine2[@CIT0048],[@CIT0050]0.08 (−0.34, 0.50)61%2[@CIT0048],[@CIT0050]0.08 (−0.13, 0.3)0%2[@CIT0048],[@CIT0050]0.18 (−0.03, 0.4)0%3[@CIT0048],49,[@CIT0050]0.01 (−0.19, 0.21)0%1[@CIT0050]0.14 (−0.1, 0.37)0%Total CIM140.13 (−0.03, 0.29)46.80%180.18 (0.05, 0.31)36.7%\*130.22 (0.06, 0.37)37.8%\*160.05 (−0.08, 0.15)0%7−0.17 (−0.48, 0.13)78%[^3] Figure 3Network of included studies with the available direct comparisons for all outcomes. (**A**) Health-related quality of life (HRQOL); (**B**) emotional well-being; (**C**) fatigue; (**D**) physical well-being; (**E**) sleep quality; (**F**) social well-being. The size of the nodes and the thickness of the edges indicate the number of included studies.**Abbreviations:** CH, Chinese herbal medicine; MCM, multimodal complementary medicine; MM, mindfulness; NS, nutritional supplement.Figure 4Direct meta-analysis of the change in health-related quality of life from endpoint to baseline.**Abbreviations:** CH, Chinese herbal medicine; MCM, multimodal complementary medicine; MM, mindfulness; NS, nutritional supplement.

Network meta-analysis of the included studies {#S0003-S2004}
---------------------------------------------

To further demonstrate the relative effect of each intervention on the HRQOL, network meta-analysis was applied and the ranking probability for each treatment was estimated. Graphical results are shown in [Figure 5](#F0005){ref-type="fig"}. The overall ranks were interpreted by the surface under the cumulative ranking (SUCRA) technique.[@CIT0061] For HRQOL, qigong + MM (SUCRA: 0.985) was shown to be the most efficacious treatment, followed by CH (SUCRA: 0.865), MCM (SUCRA: 0.65), qigong (SUCRA: 0.64), NS (SUCRA: 0.59), MM (SUCRA: 0.50), acupuncture (SUCRA: 0.44), yoga (SUCRA: 0.405), massage (SUCRA: 0.365), and control (SUCRA: 0.26), which means that all the treatments are more effective than control ([Figure 5A](#F0005){ref-type="fig"}). For emotional well-being, the ranking probability was CH \> yoga \> acupuncture \> MCM \> NS \> MM \> massage \> qigong \> control ([Figure 5B](#F0005){ref-type="fig"}). For fatigue, the ranking probability was CH \> yoga \> control \> MM \> NS \> MCM \> qigong \> acupuncture ([Figure 5C](#F0005){ref-type="fig"}). For physical well-being, the ranking probability was yoga \> MCM \> control \> NS \> acupuncture \> massage \> MM \> qigong ([Figure 5D](#F0005){ref-type="fig"}). For sleep quality, the ranking probability was control \> yoga \> qigong \> MM \> MCM \> acupuncture ([Figure 5E](#F0005){ref-type="fig"}). For social well-being, the ranking probability was control \> yoga \> NS \> MCM \> massage \> acupuncture \> qigong ([Figure 5F](#F0005){ref-type="fig"}).Figure 5Ranking probability for each treatment on health-related quality of life. Rank 1 is best and rank 6 is worst.**Abbreviations:** CH, Chinese herbal medicine; MCM, multimodal complementary medicine; MM, mindfulness; NS, nutritional supplement.

Publication bias and network coherence {#S0003-S2005}
--------------------------------------

There was no evidence of publication bias, either qualitatively based on funnel-plot asymmetry ([Figure 6](#F0006){ref-type="fig"}) or quantitatively based on Begg's regression test ([Figure 7](#F0007){ref-type="fig"}) (*P*\>0.05 for all comparisons), although the number of studies included in each comparison was small. Evaluation of the Monte Carlo error suggested adequacy of convergence, which suggested good model fit.Figure 6Funnel plot of publication bias. The dashed line represents the expected distribution of studies on the graph in the absence of publication bias.**Abbreviations:** CH, Chinese herbal medicine; MCM, multimodal complementary medicine; MM, mindfulness; NS, nutritional supplement; SMD, standardized mean difference.Figure 7Begg's funnel plot with pseudo-95% confidence limits: publication bias of complementary and integrative medicine interventions vs control.**Abbreviation:** SMD, standardized mean difference.

Quality of evidence {#S0003-S2006}
-------------------

The GRADE evidence profiles are shown in [Table 3](#T0003){ref-type="table"}. The GRADE level of meta-analysis combining direct and indirect evidence was moderate for overall CIM interventions. Regarding each CIM intervention, the GRADE quality of evidence was moderate for NS, yoga, and CH, while it was low for the remaining treatments.Table 3Overall GRADE quality of evidence from network meta-analysisCIMHRQOL changes from baselineNSModerateYogaModerateCHModerateAcupunctureLowMassageLowMMLowQigongLowQigong + MMLowMCMLow[^4]

Discussion {#S0004}
==========

As a major global health problem, cancer is a terrible disease in which complications from conventional treatments may reduce the HRQOL, which in turn affects the prognosis of patients. Therefore, more and more clinicians take HRQOL into consideration when establishing a therapeutic regimen to gain an optimal response. In the present meta-analysis, we combined direct and indirect evidence from 34 RCTs in 3,010 patients with tumor to demonstrate the potential advantage of different CIM treatments on the HRQOL. The results tended to provide moderate-quality or low-quality evidence for moderate beneficial effects of CIM interventions on the HRQOL of cancer patients. As a whole, the change in HRQOL scores was statistically significant between CIM treatment (mean range from 82.5 to 87.0) and control (mean range from 80.4 to 81.8) groups. Direct meta-analysis for total effect also showed the clearly superior efficacy of CIM treatments, although subgroup analysis demonstrated that only CH and qigong + MM were significantly favored more than usual care.

In this study, yoga was the most studied intervention, with eight trials included in the analysis, followed by NS, CH, and acupuncture. When we searched PubMed briefly with random words we found that the most papers had been published on NS, followed by acupuncture, CH, and yoga, which indicated that studies on acupuncture and CH may focus more on the unambiguous diseases rather than functional discomfort such as HRQOL. However, it may also be due to the complexity of acupuncture and CH, for which it is difficult to make a blank control, an essential requirement for RCTs.[@CIT0062]--[@CIT0064] Therefore, more RCTs on acupuncture and CH are needed to explore their effects on HRQOL of cancer patients, since they have been elaborately studied in the fields of specific diseases such as cancers. Nearly half of the included studies were conducted in the USA, which may be related to its highly developed medical research. This may influence the conclusions of our study and the multiplicity of study locations serves to increase the level of confidence in our findings.

In 2012, about 14.1 million new cases of cancer were diagnosed worldwide, with the most common types being lung (13%), breast (12%), and colorectal cancer (10%).[@CIT0065] In our analysis, breast cancer was the most studied cancer and most of the participators (92%) were female, with only one study focusing on the most widespread cancer, ie, lung cancer. Only 8% of the enrolled participants were male, which may reduce the credibility of our conclusions and make it difficult to recommend such CIM interventions among male cancer patients. Therefore, more high-quality RCTs, in greater detail and focusing on various cancers among both female and male patients, are needed and will prove valuable.

Although tests showed the clearly superior efficacy of CIM treatments in improving HRQOL, yoga seems to aggravate sleep quality (SMD −0.81 \[−1.18, −0.08\]). However, there was only one study reporting the sleep scores after treatment with yoga, so more research is needed to clarify the effects of yoga on sleep quality with more certainty.

Traditional Chinese medicine (TCM) has been long practiced and is becoming ever more widely recognized as providing curative and/or healing treatments for a number of diseases and physiological conditions.[@CIT0066] CH, acupuncture, and moxibustion are among the most popular types of TCM. CH showed a significantly superior relative effect on HRQOL, emotional well-being, and fatigue. CH is complicated and variable since it often employs combined prescriptions of multiple herbs for disease treatment.[@CIT0064] Such complexity and variability are based on an empirical set of principles that is referred to as monarch, minister, assistant, and guide.[@CIT0067] Therefore, only a small number of RCTs on CH have been conducted, most of which are of poor methodological quality owing to difficulties in the design and implementation of placebo-blinded trials.[@CIT0068] Modernization of CH, such as pharmacological studies including chemistry-focused, target-directed, and systems-biology-based studies, may promote its development. Acupuncture, however, in this analysis, did not show superiority in improving HRQOL. In accord with previous studies,[@CIT0069] yoga was found to play an important role in both emotional and physical well-being.

Although all included studies were RCTs without obvious risks of bias, limitations are present and should be accounted for when interpreting the study's findings. First, only 34 RCTs were included in the present study according to the selected criteria and no more than eight trials were conducted for each CIM intervention. The small sample size limited statistical power and study generalizability, meaning that the actual effects of CIMs may be small, although they showed superior relative effects from the existing data. Individual patient data and more detailed subgroups would have enabled us to provide more detailed insights. So, larger and more diverse samples are needed to calculate the best intervention for the exact tumor type and even the exact domains, such as emotional well-being or sleep quality, to remove the potentially confounding influence of such differences. On the other hand, other psychosocial support services such as music and art therapy or psychological counseling may also make sense, although they are excluded from the present study. The HRQOL of tumor patients is often complex and difficult to resolve, and a consistently effective CIM treatment is still lacking, making it important to examine this in future research. Second, although we have tried to figure out which intervention may be best for HRQOL by ranking the probability for each treatment using ADDIS, there is still a lack of clinical trials comparing the different efficacy of different CIMs. In addition, research focusing more on male cancer patients may make the recommended CIMs more convincing for all cancer patients. More tools which are commonly used in integrative oncology research, such as Measure Yourself Concerns and Well-being (MYCaW)[@CIT0070] and the Edmonton Symptom Assessment Scale (ESAS),[@CIT0071] may be used in future research.

Conclusion {#S0005}
==========

This systematic review provides a comprehensive overview of the relationship between different CIM interventions and the HRQOL of tumor patients. The results demonstrated clearly superior efficacy of CIM treatments in improving HRQOL, and different CIM interventions may play different roles in HRQOL such as emotional and physical well-being. More studies, especially focusing on male cancer patients, are needed to increase the confidence levels of our findings.

We thank Yanyan Wei for valuable advice and helpful discussions. This research was funded by grants from the National Natural Science Foundation of China (numbers 81430101 and 81774077).

Data sharing {#S0006}
============

Data are available from the corresponding authors at cbb8202\@126.com (BBC) or changquanling\@smmu.edu.cn (CQL).

Author contributions {#S0007}
====================

All authors contributed toward data analysis, drafting and critically revising the paper, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure {#S0008}
==========

The authors report no conflicts of interest in this work.
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[^2]: **Notes:** ^a^Duration of practicing CIM each time, how often CIM practiced. ^b^Nutrition counseling, relaxation exercises, physical exercises, stress reduction, basics of cognitive restructuring, and hydrotherapy. ^c^Conversations and dialogue with physicians, foot reflexology introduction, relaxation techniques, nutrition counseling, informative session, art therapeutic painting, physiotherapy, yoga, psycho-oncology, healing massage introduction, single sessions of foot reflexology and healing massage. ^d^Infusions with ingredients (eg, high-dose vitamin C), acupuncture, hyperthermia, movement therapy (eg, qigong), enzyme therapy, mistletoe therapy, Chinese herbal medicine. ^e^Qigong and mindfulness. ^f^Total study population.

    **Abbreviations:** CIM, complementary and integrative medicine; HRQOL, health-related quality of life; mITT, modified intention to treat (last-observation-carried-forward analysis); I, intervention group; C, control group; N/A, no detailed information; t, time; d, day; CoQ10, coenzyme Q10; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.

[^3]: **Note:** \*Statistically significant results.

    **Abbreviations:** CIM, complementary and integrative medicine; SMD, standard mean difference.

[^4]: **Abbreviations:** GRADE, Grading of Recommendations Assessment, Development and Evaluation; CIM, complementary and integrative medicine; HRQOL, health-related quality of life; NS, Nutritional supplement; CH, Chinese herbal medicine; MM, mindfulness; MCM, multimodal complementary medicine.
